Liquidia Corporation (LQDA) vs Supernus Pharmaceuticals, Inc. (SUPN)
A side-by-side comparison of Liquidia Corporation and Supernus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LQDA
Liquidia Corporation
$25.91HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SUPN
Supernus Pharmaceuticals, Inc.
$42.83HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — LQDA vs SUPN
growth of $100 · dividends reinvested · last 8yLQDA +149.0% (+12.1%/yr)SUPN -21.6% (-3.0%/yr)LQDA compounded faster over this window
LQDA SUPN
LQDA vs SUPN: by the numbers
- •SUPN is the larger company ($2.49B vs $2.30B market cap).
- •LQDA is profitable (30.74% net margin) while SUPN runs a net loss (-13.23%).
- •LQDA grew revenue faster over the past five years (128.77% vs 7.78% CAGR).
Metrics side by side
Valuation
| Metric | LQDA | SUPN |
|---|---|---|
| P/E ratio | 18.92 | N/A |
| Forward P/E | 10.42 | 16.70 |
| P/S ratio | 5.11 | 2.99 |
| P/B ratio | 11.81 | 2.41 |
| EV / EBITDA | 12.62 | N/A |
| FCF yield | 2.63% | 0.76% |
Profitability
| Metric | LQDA | SUPN |
|---|---|---|
| Gross margin | 92.48% | 88.07% |
| Operating margin | -32.45% | -5.13% |
| Net margin | 30.74% | -13.23% |
| ROE | 71.04% | -10.66% |
| ROIC | 46.99% | -10.24% |
Growth (annualized)
| Metric | LQDA | SUPN |
|---|---|---|
| Revenue CAGR (5Y) | 128.77% | 7.78% |
| FCF CAGR (5Y) | N/A | -30.77% |
| Total return CAGR (5Y) | 59.01% | 9.85% |
Frequently asked
- Which has grown faster, LQDA or SUPN?
- Over the past five years, LQDA grew revenue faster — LQDA at a 128.77% CAGR versus SUPN at 7.78%.
- Is LQDA or SUPN more profitable?
- LQDA runs the higher net margin — LQDA at 30.74% versus SUPN at -13.23%.
- How have LQDA and SUPN total returns compared?
- Over the past 5 years, LQDA delivered 59.01% and SUPN delivered 9.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Liquidia P/E ratioLiquidia ROESupernus Pharmaceuticals ROELiquidia operating marginSupernus Pharmaceuticals operating marginLiquidia revenue growthSupernus Pharmaceuticals revenue growthLiquidia free cash flowSupernus Pharmaceuticals free cash flow
Liquidia & Supernus Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.